eribulin mesylate,lenvatinib
eisai pharmaceutical
['sarcoma', 'kudos', 'eribulin']
our #leader study with lenvatinib + eribulin in advanced #lms and #lps showed orr 20% and mpfs 8.56mos! and kudos to with an excellent discussion! #asco22 #sarcoma #oralpresentation 
Dedicated sarcoma and breast medical oncologist from Taiwan. (National Taiwan University Hospital and Cancer Center)